Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of IV CR845 in hemodialysis patients with uremic pruritus
NCT03281538Phase 3Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Aug 2017
- Primary completion
- Feb 2020
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of difelikefalin in uremic pruritus, sponsored by Cara Therapeutics, Inc.. Started Aug 2017; status: completed.
02
Drugs
difelikefalin
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT03281538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281538.